Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. The company was incorporated under the laws of Australia in 1994 and has been listed on the Australian Securities Exchange (ASX), since April 30, 1999 and our ordinary shares trade under the symbol “IMC.”. Immuron completed an initial public offering on the NADAQ Capital Market in June 2017 and our American Depositary Shares and warrants are listed on NASDAQ under the symbols “IMRN” and “IMRNW”, respectively. Each ADS represents 40 of our ordinary shares, no par value.

Our validated technology platform can produce orally active polyclonal antibodies which offer targeted delivery within the gastrointestinal (“GI”) tract and essentially do not cross into the bloodstream. We believe that our lead drug candidates, currently in clinical development, have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, Clostridiodes difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.

We currently market our flagship commercial products Travelan® and Protectyn® in Australia, where both products are listed medicines on the Australian Register for Therapeutic Goods. Travelan® (AUST L 106709) is an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers’ diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. It is sold in pharmacies throughout Australia. Protectyn® (AUST L 231001) is currently sold in practitioners’ offices and is marketed as an immune supplement to help maintain a healthy digestive function and liver. We also market Travelan® in Canada (NPN 80046016) where it is licensed as a natural health product indicated to reduce the risk of travelers’ diarrhea, and presently market Travelan® in the U.S. as a dietary supplement for digestive tract protection.